RxDoctor Payments Data

Vicky Chen-Yang, MD

Internal Medicine · Peoria, AZNPI 1033159207

Payments from drug & device makers

$1,073in general payments, 2019–2025

Across 48 payments — averaging $22.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$275
  • AstraZeneca$170
  • Johnson & Johnson$148
  • Pfizer$127
  • GSK$93
  • Novo Nordisk$85
  • plus $176 from 5 others

What the payments were for

  • Food & beverage$1,06199%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,073 in reported general payments places this provider in the 75th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$142,313
Medicare patients
348
Services billed
2,046

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$149,927
MounjaroTirzepatide37$47,466
JardianceEmpagliflozin41$45,792
WegovySemaglutide19$33,231
FarxigaDapagliflozin Propanediol25$33,082
TrulicityDulaglutide18$32,825
EliquisApixaban32$30,719
JanuviaSitagliptin Phosphate20$29,741
RybelsusSemaglutide12$20,471
XareltoRivaroxaban11$18,106
VascepaIcosapent Ethyl14$15,089
Repatha SureclickEvolocumab11$12,429
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$10,608
Breo ElliptaFluticasone/Vilanterol11$6,438
SynthroidLevothyroxine Sodium56$4,417

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy, Rybelsus$85$203,629108 claims
Lilly USA, LLCMounjaro, Trulicity$27$80,29155 claims
AstraZenecaFarxiga, Breztri Aerosphere$170$43,69039 claims
PfizerEliquis$127$30,71932 claims
MerckJanuvia$58$29,74120 claims
Johnson & JohnsonXarelto$148$18,10611 claims
GSKBreo Ellipta$93$6,43811 claims
AbbVieSynthroid$34$4,41756 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Peoria

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →